CD163 and cancer: A recent study that investigated multiple macrophage markers in relation to breast cancer outcomes showed that when examining the ER-positive versus ER-negative groups separately, high expression of CD163 was associated with improved OS in ER− cases, but not in ER+ cancers [31].